Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020

Lorcaserin Departs, Leaving More Questions than Answers

(2020) Rekha Kumar et al.   Obesity

Pharmacotherapy for Obesity—Trends Using a Population Level National Database

(2020) Abbinaya Elangovan et al.   OBESITY SURGERY

Updates on obesity pharmacotherapy

(2018) Amanda Velazquez et al.   Annals of the New York Academy of Sciences

Safety and tolerability of new-generation anti-obesity medications: a narrative review

(2018) Dhiren K Patel et al.   POSTGRADUATE MEDICINE

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

(2018) Erin A. Bohula et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current pharmacotherapy for obesity

(2017) Gitanjali Srivastava et al.   Nature Reviews Endocrinology

Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance

(2016) L Aagaard et al.   INTERNATIONAL JOURNAL OF OBESITY

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events

(2016) Rohan Khera et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants

(2016) Dagfinn Aune et al.   BMJ-British Medical Journal

BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants

(2016) Dagfinn Aune et al.   BMJ-British Medical Journal

Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force

(2013) Erin S. LeBlanc et al.   ANNALS OF INTERNAL MEDICINE

Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes

(2013) KJ Neff et al.   BMC Medicine

Global Patterns of Adverse Drug Reactions Over a Decade

(2013) Lise Aagaard et al.   DRUG SAFETY

Long-term Drug Treatment for Obesity

(2013) Susan Z. Yanovski et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Use of Prescription Antiobesity Drugs in the United States

(2013) Christian Hampp et al.   PHARMACOTHERAPY

Anti-obesity drugs: past, present and future

(2012) R. J. Rodgers et al.   Disease Models & Mechanisms

Anti-obesity drugs: a review about their effects and their safety

(2012) Giuseppe Derosa et al.   Expert Opinion On Drug Safety

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)

(2011) David B. Allison et al.   Obesity

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

(2010) W. Philip T. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

New central targets for the treatment of obesity

(2009) Bruce J. Sargent et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis

(2009) K. Johansson et al.   Obesity Reviews